Compare AbbVie Inc (ABBV) vs Allegion PLC (ALLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Allegion PLC — how do they compare? AbbVie Inc trades at $250.69 (market cap $439.59B), while Allegion PLC trades at $163.36 (market cap $14.13B). The key difference: AbbVie Inc is far larger — about 31.1× Allegion PLC's market cap, and AbbVie Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| ABBV | ALLE | |
|---|---|---|
Market Cap | $439.59B | $14.13B |
Sector | Health | Industrials |
52-Week High | $263.58 | $179.77 |
52-Week Low | $197.38 | $125.65 |
Enterprise Value | $503.84B | $15.84B |
Dividend Yield | 2.78% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $253.54, up 1.44% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust revenue growth driven by Skyrizi and Rinvoq offset Humira declines, though net margins have compressed. The stock is near resistance at $253, with institutional buying and positive clinical news supporting momentum.
Outlook remains positive with a $278.69 consensus price target, but high P/E of 70.27 and looming patent cliffs in the 2030s pose risks. Dividend growth and pipeline advancements offer upside, yet valuation and competitive pressures warrant caution for near-term investors.
ALLE trades at $166.18, up 0.39% on the day, showing strong momentum following better-than-expected Q2 2026 earnings. The stock demonstrates robust fundamentals with 15.36% net income margin and 33.73% ROE, though recent quarters show mixed earnings performance. Technical indicators suggest bullish momentum with the current price near resistance levels. Recent institutional buying and positive analyst coverage highlight growing confidence in the security products provider's growth trajectory.
Outlook remains positive with raised 2026 guidance and strong Americas segment performance driving optimism. Investment opportunity lies in continued margin expansion and market share gains, while risks include international segment weakness and rising input costs. The stock trades above consensus price target but offers potential upside to high target of $170.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
